GIinteractive11 | Case 3 - Gastric Cancer


A 78-year-old woman with metastatic HER2-positive (FISH 6.9) adenocarcinoma of the GE junction demonstrates a good response to FOLFOX/trastuzumab. Oxaliplatin is discontinued because of neurotoxicity.

Which agents, if any, would you continue?

Would you generally administer trastuzumab (with chemotherapy) to a patient with metastatic gastric cancer that is IHC 1+ but FISH-positive (ratio 6.9)?